Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bortezomib + fludarabine + cyclophosphamide
- Development stage
- Unknown
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination chemotherapy regimen consisting of bortezomib (a proteasome inhibitor), fludarabine (a purine nucleoside analog), and cyclophosphamide (an alkylating agent). This regimen is primarily used for the treatment of relapsed or refractory mantle cell lymphoma (MCL). The combination works through multiple mechanisms: bortezomib blocks proteasome activity disrupting cancer cell growth, fludarabine inhibits DNA synthesis, and cyclophosphamide damages DNA by cross-linking with DNA strands.
- Other names
- B-FCBFC
02
Targets
DNAPSMB5 (Proteasome subunit beta Type-5)DNA polymerase family
Beyond the preview
Go deeper on bortezomib + fludarabine + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bortezomib + fludarabine + cyclophosphamide.